MIAMI BEACH, FL / ACCESSWIRE / July 29, 2019 / Soligenix (NasdaqCM: SNGX) stock is trending higher as the company gets closer to releasing the interim efficacy analysis from its Phase III DOM-INNATE trial. Since the beginning of June, SNGX stock is higher by 52%, and the expectation from analysts at Zacks Small-Cap research expect the trend to continue. That expectation is supported by a research report published in July that highlighted the potential in the SNGX pipeline and providing an $8.00 price target in the next 12-months. Assuming their models are correct, a move to the $8.00 level will serve up a more than 580% increase from the stocks most recent price of $1.06 per share.

The recent enthusiasm comes from the already known data from the SGX942 Phase II trial. And, because interim analysis is expected for the Phase III trial in no more than two months, investors appear to want to take a position in the company ahead of the release. SNGX expects that the DOM-INNATE trial will complete enrollment of approximately 190 subjects in 2019 and release top-line final results in the first half of 2020. The Phase III trial, is a randomized, multinational, double-blind, placebo-controlled trial to evaluate SGX942 for the treatment of severe oral mucositis in patients with squamous cell carcinoma of the oral cavity that are undergoing chemoradiation therapy.

Soligenix Targeting Oral Mucositis Market With SGX942; Phase III Interim Analysis In September

Soligenix’s, SGX942 program, is attracting analyst and investor attention based on positive results to date and also because the drug is targeting oral mucositis, an important unmet medical need that is in high demand. The Phase II clinical data of SGX942 generated promising results during its proof-of-concept trial in 2015, where the drug was administered to 111 head and neck cancer patients and showed that the drug provided a 67% reduction in the duration of severe oral mucositis compared to the placebo group, reducing the median duration of severe oral mucositis from 30 days (one month) in the placebo group to just ten days in the treated group. Moreover, in addition to the 67% reduction in duration, the Phase II SGX942 study met its pre-specified secondary endpoint that demonstrated a reduction in the median duration of ulcerative oral mucositis.

From a regulatory and approval perspective, the drug to date has been safe, well-tolerated, and appears to have increased the response of cancer treatment by showing that those treated with SGX942 during their chemoradiation procedure experienced a higher rate of complete tumor resolution compared to those in the placebo group. Consequently, the results contributed to the most critical correlation of benefit that showed a positive trend (“P-value” of <0.1) in overall survival for SGX942 treated patients at one-year follow-up evaluations.

Pipeline Promise And Multiple Potential Catalysts in 2020

In addition to the pending DOM-INNATE interim results expected in September and the top-line Phase III study results in first half 2020, Soligenix is also on track with its second pivotal Phase III clinical trial, referred to as the “FLASH” study, evaluating the benefits of SGX301 in patients with cutaneous T-cell lymphoma (CTCL). The Company released in October 2018 that they received a positive recommendation from the independent Data Monitoring Committee (DMC) following interim efficacy analysis in which the independent DMC recommended continuing enrollment and to include an additional approximate 40 patients into the trial to maintain the high statistical power of 90% for the trial’s primary endpoint.

The Phase III trial uses a novel photodynamic therapy (SGX301), utilizing synthetic hypericin that is activated by safe, visible light, via a proprietary light device. The treatment includes a topically applied dose of synthetic hypericin to lesions on the skin, which has shown a much higher uptake by malignant cells in comparison to healthy, normal cells. Following a period between 16-24 hours of application, the treated area is then exposed to visible fluorescent light, where studies have confirmed that the exposure to light results in the production of singlet oxygen. That reaction from the light is shown to have a unique ability to stimulate the initiation of apoptosis (cell death), resulting in the death of the malignant T-cells.

The FLASH clinical trial is on pace to enroll a total of approximately 160 patients, and as of the update from SNGX, more than 120 patients have already been treated. Similar to its other ongoing Phase III trial, FLASH is a randomized, double-blind, placebo-controlled study that is evaluating SGX301 in patients with either Stage 1A, 1B, or 2A mycosis fungoides, the most common type of CTCL, with testing taking place in approximately 30 treatment centers across the United States. The primary endpoints of the trial are the percentage of patients achieving a > 50% reduction in the total Composite Assessment of Index Lesion Disease Severity (CAILS) score at the end of the first eight-week cycle compared to the baseline. Secondary endpoints include the duration of response, the degree of lesion improvement, and treatment safety.

Also setting up to provide a near-term catalyst, the FLASH trial is expected to be completed by the end of 2019, followed with final topline data during the first quarter of 2020. If results are positive, it can compound the benefits of expected interim results from its pipeline partner SGX942, which has led to analysts increasing their valuation models ahead of that release.

Bio-defense Vaccine Programs Can Be Substantial Contributors; RiVax® Leads Way

In addition to the late-stage Phase III drug trials, Soligenix is advancing its bio-defense programs that are getting financial support through non-dilutive government grants and contracts. Two products are currently being evaluated, ThermoVax®, and RiVax®. Each can provide significant market opportunities in critical areas of need.

ThermoVax® is a proprietary stabilizing platform technology that allows vaccines comprised of an aluminum salt adjutant to be kept out of cold storage without affecting the potency of the drug. The platform can be a breakthrough that can eliminate the need for cold storage, contributing to multi-purpose applications and provide critically needed treatment in the battlefield, during extreme power-outage situations, and large scale triage situations. In addition to its stabilizing effect, other vital benefits include ease of storage and for the ability to allow for a national and strategic stockpile of essential vaccines. The ThermoVax® technology has already shown demonstrably positive results with RiVax®, the company’s ricin vaccine. Independent studies showed that ThermoVax® is capable of providing potency protection for the RiVax® vaccine for up to one year at 104° Fahrenheit. Additionally, ThermoVax® demonstrated its ability to protect the potency of vaccine candidates to treat anthrax, HPV, and Ebola for up to twelve weeks at the same high temperatures.

Soligenix lead bio-defense vaccine program, RiVax® (using ThermoVax®), is a heat stable vaccine being developed to protect against exposure to ricin, a lethal toxin used in chemical warfare. During a Phase Ia study, SNGX demonstrated that its vaccine antigen, an abbreviated version of ricin toxin A chain with no biological activity, is non-toxic and able to induce an immunogenic response. Also contributing to its profile, the alum-adjuvanted RiVax® was also shown to be safe and well-tolerated in a Phase Ib study in human volunteers. Importantly, the antibodies induced through immunization with RiVax® have demonstrated complete protection from a lethal dose of aerosolized ricin in a rhesus macaques vaccine trial conducted in 2015. Soligenix is expected to seek expedited FDA approval for the vaccine under the “animal rule” that relies on studies successfully conducted in non-primates.

In 2018, the compelling therapeutic benefits of the vaccine were presented at the Fourth International Conference on Vaccines Research and Development. The vaccine candidate has earned funding through non-dilutive grants awarded from the NIH (approximately $25 million thus far) and through an up to $24.7 million contract entered into with the NIH in 2014. Based on the encouraging data in an important sector, SNGX is also evaluating the opportunity to apply for a priority review voucher (PRV), which can be a valuable asset to the RiVax® program. Notably, these PRV’s are transferable, and recent PRV’s have traded hands in the biotech and pharma sector at values that exceed $100 million.

SNGX Is Advancing Multiple Opportunities In 2019-2020

For Soligenix investors, September may be the start to a breakout move for the remainder of 2019-2020. If the data from the SGX942 trial interim result are positive, SNGX may become well-positioned to capitalize on the first of two drugs, SGX942 and SGX301, that can combine to bring more than $500 million in annual revenues. But, investors should not discount the vaccine programs that can also add considerable value to their respective approvals.

Trading at $1.06 as of the close of trading on July 26th, the company is well below recent analyst price targets of $8.00. And, while the stock traded down in sympathy with overall weakness in biotech stocks last week, SNGX appears to be ideally positioned to further its growth by capitalizing on its government funding and its current cash position of $7 million as of its latest filing. For investors, the recent weakness may bring greater opportunity as SNGX is advancing at least five programs targeting markets that can each generate hundreds of millions in potential peak revenues.

Furthermore, with at least two potential pivotal Phase III catalysts expected within the next six to nine months, investors are unlikely to ignore the blue-sky value ahead of its trial release, with the first scheduled in September. And, if that is indeed the case, the stock will likely resume its upward momentum in the coming days.

Media Contact:

Perceptive Advisors, LLC
Kenny Soulstring
Miami Beach, Florida
Editorial@soulstringreport.com

SOURCE: Perceptive Advisors, LLC

ReleaseID: 553764

Finance and Technology Experts David Fergusson and Carlos Moreira Join Academic, Corporate, Policy and Religious Leaders to Deliberate ‘Technology and Human Flourishing’

VATICAN CITY & ROME, ITALY / ACCESSWIRE / July 29, 2019 / ​Humanity 2.0, a non-profit human progress accelerator and social impact initiative with the support of the Pontifical Lateran University at the Vatican, announces a dynamic forum, ​Technology and Human Flourishing, ​to be held today July 29 at the Collegio Teutonico in Vatican City.

This exclusive gathering of technology, corporate, finance, government, academic, ecclesiastic and media leaders is an interactive forum to catalyze awareness and establish the best path forward with humanity and technology in harmony.

The critical discussion will be led by David Fergusson and Carlos Moreira, authors of the new best-selling book, The transHuman Code​ and the author of ​Artificial Humanity​, Father Phillip Larrey, together with Matthew Sanders, the CEO of Humanity 2.0. The think tank forum – ‘TransHuman Code Meeting of The Minds’will focus on the subject of these thought-provoking ground breaking books.

David Fergusson, co-author of ​The transhuman Code​ states “​In this, the age of technological revolution, advocating and innovating the greatest good for all humanity is paramount to realizing the full potential of our future.”Fergusson is the Executive Director of M&A for the leading US investment bank Generational Equity and Chairman of The M&A Advisor.

“Never has there been a more important time in our history for business, government, academic and religious leaders to align on the core tenants of humanity, states Carlos Moreira, co-author of ​The transHuman Code. Swiss cybersecurity and IoT pioneer, Carlos Moreira is the CEO of Wisekey International.

“Humanity is at a crossroads and the time has come for us not just to think collaboratively, but to put our thoughts into action”, states Matthew Sanders, CEO of Humanity 2.0. “This event assembles thought leaders from around the world to collaboratively act on providing global solutions.”

“Technology is shaping the fabric of our society”, states Rev. Philip Larrey, author of ​Artificial Humanity and​ Connected World​. “And while Artificial Intelligence has captured the imagination of a generation, we need to challenge all to ensure that the ethical foundation is firmly established to fully thrive.”

Matt Bird, Host of the Traders Network Show and Advisor to Humanity 2.0, commented; enterprise adoption of new technologies including Artificial intelligence (AI), gives organizations great power to create automated efficiency. It’s our duty and responsibility as corporate leaders to make sure that technology doesn’t displace humanity but empowers humans to make better decisions in the work place – not replace them.

“The transHuman Code Meeting of The Minds” originated in Davos, Switzerland in 2015 where global leaders assembled to discuss the impending impact of the 4thIndustrial Revolution. Since that ground breaking event, authors Fergusson and Moreira have brought technology, corporate, finance, government, academic, and media leaders together at gatherings across the world to discuss how we can program our future for the betterment of all. This extensive research, culminated in the publishing of the book, The transHuman Code, in June of this year.

At the “transHuman Code Meeting of The Minds” assembly at the Vatican today, Humanity 2.0 and the book’s authors announced a global institutional tour featuring town hall style meetings of all technology stakeholders at leading universities over the year ahead.

For media inquiries concerning the event please contact Matt Bird matt.bird@1800pr.com or Nicole Liddy nicole.liddy@1800pr.com

About Humanity 2.0

Humanity 2.0 is a vehicle for facilitating collaborative ventures between the traditionally siloed public, private and faith-based sectors. Its mission is to identify impediments to human progress and then work cross-sector to remove them. Developed in collaboration with the Dicastery for Promoting Integral Human Development at the Holy See and a consortium of leaders and luminaries, Humanity 2.0 is an agent of the common good and a believer in the need for a shared horizon to unite humankind.

More Information: https://humanity2-0.org

About OISTE.ORG

Founded in Switzerland in 1998, OISTE.ORG was created with the objectives of promoting the use and adoption of international standards to secure electronic transactions, expand the use of digital certification and ensure the interoperability of certification authorities’ e-transaction systems. The OISTE Foundation is a not for profit organization based in Geneva, Switzerland, regulated by article 80 et seq. of the Swiss Civil Code. OISTE is an organization in special consultative status with the Economic and Social Council of the United Nations (ECOSOC) and belongs to the Not-for-Profit constituency (NPOC) of the ICANN.

More Information: http://www.oiste.org/.

CONTACTS:

Communications Contact:

Matt Bird
CEO @1800pr
1-800-PublicRelations, Inc.
(P) +1 (646) 401-4499
(E) matt.bird@1800pr.com

SOURCE: Humanity 2.0

ReleaseID: 553782

Company to Initiate Search for New President and CEO

ATLANTA, GA / ACCESSWIRE / July 29, 2019 / Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of integrated solutions, technology-enabled services and analytics supporting revenue cycle optimization for healthcare enterprises, today announced that Wyche T. (“Tee”) Green, III will serve as Interim President and Chief Executive Officer, replacing David W. Sides, who has taken a position with another company, effective immediately.

Mr. Green is currently Chairman of the Board of Directors of Streamline Health and will continue in that capacity as the Board and executive leadership team focus on continuing its revenue growth campaign primarily through eValuator ™ its cloud-based, automated pre-bill coding analysis platform. The Company will launch a robust search to identify a permanent President and Chief Executive Officer with a proven track record of generating meaningful, on-going revenue growth.

Streamline Health is leading an industry movement to improve healthcare providers’ financial performance by moving mid-to-late revenue cycle interventions upstream, optimizing coding accuracy for every patient encounter prior to bill submission. By improving coding accuracy before billing, providers can reduce lost revenue, mitigate overbill risk, and reduce denials and days in A/R.

Speaking on behalf of the Board, Mr. Green stated, “We appreciate David’s service to Streamline Health and our valued clients as President and Chief Executive Officer for the last four years. We are intensifying our focus on a sales and marketing strategy to grow revenue while delivering an exceptional customer experience. We believe that hiring a new President and Chief Executive Officer with demonstrated expertise in accelerating sales reinforces the Company’s investment this year in a new sales leader and advisory board members.”

Mr. Green is the former Chief Executive Officer and Executive Chairman, as well as Co-Founder, of Greenway Health, LLC, an electronic health record and practice management company. Mr. Green has deep expertise in building a high performing, customer-centric corporate culture and energizing sales, marketing and business development activities. Mr. Green currently serves as the Chairman and Chief Executive Officer of 121G, LLC, a Georgia-based private investment company that he founded in 2013.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge­ – producing actionable insights that support revenue cycle optimization for healthcare enterprises. We deliver integrated solutions, technology-enabled services and analytics that empower providers to drive revenue integrity in a value-based world. We share a common calling and commitment to advance the quality of life and the quality of healthcare – for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which provides a “safe harbor” for such statements in certain circumstances. The forward-looking statements include statements or expectations regarding the Company’s strategic initiatives, executive search and growth strategy. These statements are based upon current expectations, beliefs and assumptions of Company management, and there can be no assurance that such expectations will prove to be correct. Because forward-looking statements involve risks and uncertainties and speak only as of the date on which they are made, actual events could differ materially from those discussed in the forward-looking statements as a result of various factors discussed in greater detail in the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such statements and to consult the Company’s most recent Annual Report on Form 10-K and other filings with the SEC for additional risks and uncertainties that may apply to the Company’s business and the ownership of the Company’s securities. The Company’s forward-looking statements are presented as of the date made, and the Company does not undertake any duty to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contact:

Randy Salisbury
SVP, Chief Marketing Officer
(404) 229-4242
randy.salisbury@streamlinehealth.net

SOURCE: Streamline Health Solutions, Inc.

ReleaseID: 553761

LOS ANGELES, CA / ACCESSWIRE / July 29, 2019 / Cheapquotesautoinsurance.com has launched a new blog post that presents several smart methods that can help car owners cut costs on car insurance.

For more info and free online quotes, please visit https://cheapquotesautoinsurance.com/cut-costs-car-insurance/.

In most states, car insurance is required by law. For many, car insurance can be a costly investment that can seriously affect the family’s budget. Fortunately, there are many ways that can help anyone pay less on car insurance.

To cut costs on car insurance, drivers can follow the next tips:

Keep the car parked in a garage. Insurance companies prefer cars that are kept in garages and for this reason, they will lower the insurance rates. Cars that are being kept in a garage are less likely to be stolen and are better protected against the severe weather.
Increase deductibles. Policyholders can agree to pay more money out of their pockets, before the insurance kicks in. Doing this will lower the price of insurance. However, drivers should ensure they will save enough money in order to pay for the deductibles if they will have to file a claim.
Drive a safe car. Exotic sports cars or limousines are expensive to insure. These cars are expensive to repair and are favorite targets for thieves. Instead, drivers should try to insure slightly used minivans, SUV’s, or sedans that are equipped with several safety devices. These types of vehicles are cheaper to insure and they cost less to repair.
Keep a good credit score or improve it. Insurance companies will look at the drivers’ credit score before granting them coverage. Insurers claim they found a correlation between a driver’s credit score and his chances to file for a claim. For this reason, drivers with a poor credit score will pay more on insurance premiums, while policyholders with good or excellent credit score will less.
Bundle multiple policies. One of the easiest methods used by drivers to save money on car insurance is to bundle policies. Drivers that own at least two vehicles can combine their policies at one insurer and obtain a multi-car discount. Also, drivers can combine different types of policies like car insurance with life insurance, homeowner’s insurance, or health insurance and obtain a multi-policy discount.

For additional info, money-saving tips and free car insurance quotes, visit https://cheapquotesautoinsurance.com/

Cheapquotesautoinsurance.com is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

“For many, car insurance is a necessary expense. To cut the costs of insurance, policyholders can bundle multiple policies and drive a safe vehicle,” said Russell Rabichev, Marketing Director of Internet Marketing Company.

CONTACT: cgurgu@internetmarketingcompany.biz

SOURCE: Internet Marketing Company​​​​​​​

ReleaseID: 553756

DENVER, CO / ACCESSWIRE / July 29, 2019 / International Cannabrands Inc. (CSE: JUJU) (the “Company”) is pleased to announce that its 51% subsidiary La Vida Verde, Inc., (“LVV”), expects to record a 44.7% growth in Q2 revenue over Q1 of this year.

For Q2 of 2019, LVV recorded approximately $1.79 million in revenue, a $552 thousand increase over Q1 2019. This is a 5.4% decrease over Q2 2018, net of the prior year loss of a major customer no longer in business in California. All figures are unaudited and based on Management’s review of LVV’s results as determined as at the date hereof.

Selected financial information for LVV for the three months ended June 30, 2019 (all of which has been prepared by LVV’s management), includes the following: Revenue of $1,786,000; Net Income of $38,000; Total Assets of $2,946,000 and Total Liabilities of $204,000.

After replacing an underperforming distributor in Q1, LVV brought product back in-house in early April. Through the subsequent expansion of their in-house sales efforts, the team was able to outperform the previous quarter and expects to see further growth as the year continues.

“We are tremendously pleased with La Vida Verde’s strong performance, and we anticipate they’ll continue to increase market share in existing and new territories within California,” shared Steve Gormley, CEO of the Company.

In addition to an investment in in-house sales and marketing, LVV has also expanded its reach through a delivery partnership with Driven (see press release dated March 28, 2019), a distribution partnership with Nabis (see press release dated May 6, 2019), a sales agreement with Bettie Janes (see press release dated June 25, 2019) and the expansion of supply and distribution into Nevada through the agreement with Flower One (see press release dated July 11, 2019).

Bryce Berryessa, President of La Vida Verde commented: “By leveraging these outstanding partners alongside LVV’s team, we’re looking to establish a powerful sales and distribution engine servicing the entire state of California. We look forward to further expanding our footprint and getting our family of products into the hands of new customers.”

Steve Gormley commented: “Traditional operating lines are just not available to junior companies and particularly those in the cannabis space. This facility allows the Company to smooth out its cash flow and back stop its operations if needed, while we navigate our early design. We need to employ all the tools we can to ensure the success and growth of the Company, and we feel the team we have chosen in Sea Otter is first class.”

About La Vida Verde, Inc.

In addition to LVV’s wholesale flower, packaged flower and pre-rolls, its differentiating products include gummies, upscale protein bars, new chocolate forms and super cookies. LVV Brands currently include Skunk Feather Cannabis™ and Blank Brand™. LVV has been operating in California since 2015, and currently has extraction, manufacturing and distribution capability. LVV is a leader in the extraction field, being one of the first to incorporate full spectrum testing in every product, testing for potency, terpenes, pesticides and residual solvents. Its concentrates are pharmaceutical grade and free of any pesticides, microbial contaminants, heavy metals or additives. LVV has recently doubled its manufacturing capability and has installed state-of-the-art technology. LVV believes that the best medicine starts with the food you eat and it takes pride in producing products for people who are search for a natural and healthy alternative for nurturing their bodies. All its products use only healthy fats, are vegan, organic, gluten-free, paleo friendly and low glycemic.

About International Cannabrands (ICI)

ICI’s strategy centers on acquiring micro brands, distribution and specific manufacturing/cultivation companies in the cannabis space. The Company’s business model is to generate revenue from cannabis cultivation, brands ranging from flower to edibles and from THC to CBD, oil extraction, ancillary products and apparel in the United States. ICI markets products with THC content where that practice has been legalized at the state level through either medicinal or full recreational use. ICI also markets products containing CBD in the US and internationally. ICI owns 51% of La Vide Verde, Inc. and has the exclusive rights to Julian Marley’s JuJu Royal™ brand. The Company believes as the legal cannabis market evolves, high-quality, unique products will increasingly capture market share and provide a valuable platform for growth.

International Cannabrands Contact:

Steve Gormley Chief Executive Officer 1045 Lincoln Street, #106 Denver, Colorado 80203 Ph: (323) 828-4321 or steve.gormley@intlcannabrands.com Media Inquiries: media@jujuroyal.net.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Disclaimer concerning Forward-looking Statements

Certain statements included herein constitute “forward-looking statements” relating to the performance of LVV and the Company, within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Investors are cautioned not to put undue reliance on forward-looking statements. Additional risks and uncertainties regarding the Company are described in its publicly-available disclosure documents filed by the Company on SEDAR (www.sedar.com). The forward-looking statements contained in this news release represent the Company’s expectations as of the date of this news release, or as of the date they are otherwise stated to be made, and subsequent events may cause these expectations to change. Except as required by law, the Company does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

SOURCE: International Cannabrands Inc.

ReleaseID: 553768

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Civeo Corp. (NYSE: CVEO) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 29, 2019 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-07F2F3A05B4B2

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 553619

TORONTO, ON / ACCESSWIRE / July 29, 2019 / Wi2Wi Corporation (Wi2Wi or the Company) announces that Messrs. Gary DuBroc, Francesco Ferlaino, Matthew Balazsi, Zachariah Mathews and Ms. Carol Hess were elected as directors of the Company at the annual and special meeting of shareholders held on July 26, 2019 (the AGM). Following the AGM, the Board of directors appointed Mr. Gary DuBroc as Chairman of the Board of directors.

For further information, please contact:

Dawn Leeder
Chief Financial Officer
608 203 0234
dawn_l@wi2wi.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Wi2Wi Corporation

Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company’s products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi’s products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi’s manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi’s strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi’s end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer’s representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales.

Forward-Looking Statements: This news release contains certain forward-looking statements, including management’s assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company’s control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company’s actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company’s operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

SOURCE: Wi2Wi Corporation

ReleaseID: 553758

NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Hypera SA (OTCPINK: HYPMY) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 29, 2019 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-1512D581BA1BC

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 553615